AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB INPATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMALRESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT
A study for patients with Multiple Sclerosis (MS) using study drug ocrelizumab for disease-modifying treatment
Sponsor: Genentech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ8211
U.S. Govt. ID: NCT02637856
Contact: Claire Riley: 212-305-6876 / csr53@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if ocrelizumab (study drug) will stabilize, or potentiallyimprove the signs and symptoms of your MS. Ocrelizumab is a type of drug called amonoclonal antibody. Monoclonal antibodies act like your bodys immune system andattach to certain cells in order to attack germs and other illnesses in your body.Ocrelizumab attaches to certain types of cells (B cells) that are thought to play a role in
This study is closed
Investigator
Claire Riley, MD
Do You Qualify?
Have you been diagnosed with MS? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Claire Riley
csr53@cumc.columbia.edu
212-305-6876
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE